Search Results - Angela Howes
- Showing 1 - 3 results of 3
-
1
-
2
Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open‐label phase 3 study by Xiaojun Huang, Lugui Qiu, Jie Jin, Daobin Zhou, Xiequn Chen, Ming Hou, Jianda Hu, Yu Hu, Xiaoyan Ke, Junmin Li, Yingmin Liang, Ting Liu, Yue Lv, Hanyun Ren, Aining Sun, Jianmin Wang, Chunting Zhao, Mariya Salman, Steven Sun, Angela Howes, Jingzhao Wang, Peng Wu, Jianyong Li
Published in Cancer Medicine (2018-04-01)Get full text
Article -
3
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials by Jennifer R. Brown, Javid Moslehi, Susan O’Brien, Paolo Ghia, Peter Hillmen, Florence Cymbalista, Tait D. Shanafelt, Graeme Fraser, Simon Rule, Thomas J. Kipps, Steven Coutre, Marie-Sarah Dilhuydy, Paula Cramer, Alessandra Tedeschi, Ulrich Jaeger, Martin Dreyling, John C. Byrd, Angela Howes, Michael Todd, Jessica Vermeulen, Danelle F. James, Fong Clow, Lori Styles, Rudy Valentino, Mark Wildgust, Michelle Mahler, Jan A. Burger
Published in Haematologica (2017-10-01)Get full text
Article
